Last 12 months
Inside the activity.
0 purchase rows · 17 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 4 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2021 Filed Jul 22, 2021 20:34 UTC |
Privitera SalvatoreChief Technical Officer
|
SaleCommon Stock | 2,000 | $80.00 | $160,000.00 |
DisclosureSEC source: 0001209191-21-047752 · doc4.xml · nonDerivative · entry 1 Privitera Salvatore · CIK 0001336063 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,227 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 07:59 UTC |
Austin TonyaChief Human Resources Officer
|
SaleCommon Stock | 493 | $78.03 | $38,468.79 |
DisclosureSEC source: 0001209191-21-047328 · doc4.xml · nonDerivative · entry 1 Austin Tonya · CIK 0001861968 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,792 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:37 UTC |
Doraiswamy VinayakChief Scientific Officer
|
SaleCommon Stock | 7,672 | $83.12 | $637,696.64 |
DisclosureSEC source: 0001209191-21-046673 · doc4.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.36 to $83.96 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:03 UTC |
Dahlquist Karl S.Chief Legal Officer
|
SaleCommon Stock | 336 | $79.53 | $26,722.08 |
DisclosureSEC source: 0001209191-21-044872 · doc4.xml · nonDerivative · entry 2 Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,801 F3 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 07:54 UTC |
Collar Mark ADirector
|
SaleCommon Stock | 3,000 | $79.61 | $238,830.00 |
DisclosureSEC source: 0001209191-21-045220 · doc4.xml · nonDerivative · entry 1 Collar Mark A · CIK 0001426353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,307 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $79.19 to $80.18 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:13 UTC |
Doraiswamy VinayakChief Scientific Officer
|
GrantCommon Stock | 428 | $45.72 | $19,568.16 |
DisclosureSEC source: 0001209191-21-044939 · doc4.xml · nonDerivative · entry 1 Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,547 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:20 UTC |
Austin TonyaChief Human Resources Officer
|
GrantCommon Stock | 193 | $45.72 | $8,823.96 |
DisclosureSEC source: 0001209191-21-044957 · doc4.xml · nonDerivative · entry 1 Austin Tonya · CIK 0001861968 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,285 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:03 UTC |
Dahlquist Karl S.Chief Legal Officer
|
GrantCommon Stock | 428 | $45.72 | $19,568.16 |
DisclosureSEC source: 0001209191-21-044872 · doc4.xml · nonDerivative · entry 1 Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,137 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:08 UTC |
Wirick Angela LChief Financial Officer
|
GrantCommon Stock | 213 | $45.72 | $9,738.36 |
DisclosureSEC source: 0001209191-21-044902 · doc4.xml · nonDerivative · entry 1 Wirick Angela L · CIK 0001819885 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,880 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:16 UTC |
CARREL MICHAEL HDirector · President, CEO, & Director
|
GrantCommon Stock | 251 | $45.72 | $11,475.72 |
DisclosureSEC source: 0001209191-21-044946 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,541 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:10 UTC |
Privitera SalvatoreChief Technical Officer
|
GrantCommon Stock | 171 | $45.72 | $7,818.12 |
DisclosureSEC source: 0001209191-21-044923 · doc4.xml · nonDerivative · entry 1 Privitera Salvatore · CIK 0001336063 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,227 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 12:10 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
SaleCommon Stock | 4,119 | $80.00 | $329,520.00 |
DisclosureSEC source: 0001209191-21-043590 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,689 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · derivative · entry 4 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
SaleCommon Stock | 6,000 | $76.36 | $458,160.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,808 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.11 to $77.13 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
SaleCommon Stock | 15,000 | $76.36 | $1,145,400.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,808 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.11 to $77.13 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 12:54 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
Exercise / conversionCommon Stock | 15,000 | $18.30 | $274,500.00 |
DisclosureSEC source: 0001209191-21-042665 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 16:23 UTC |
Austin TonyaChief Human Resources Officer
|
SaleCommon Stock | 2,620 | $76.36 | $200,063.20 |
DisclosureSEC source: 0001209191-21-041995 · doc4.xml · nonDerivative · entry 1 Austin Tonya · CIK 0001861968 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,092 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.82 to $76.91 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 12:33 UTC |
Telman Deborah HDirector
|
GrantCommon Stock | 2,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041246 · doc4.xml · nonDerivative · entry 1 Telman Deborah H · CIK 0001860008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,245 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest 33% annually over three years from date of grant. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 12:30 UTC |
Yuen MaggieDirector
|
GrantCommon Stock | 2,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041244 · doc4.xml · nonDerivative · entry 1 Yuen Maggie · CIK 0001796057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,245 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest 33% annually over three years from date of grant. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC |
GROVES REGINA EDirector
|
SaleCommon Stock | 4,208 | $71.95 | $302,765.60 |
DisclosureSEC source: 0001209191-21-036518 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,350 F1 · price: This transaction was executed in multiple trades at prices ranging from $71.81 to $72.07 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2021 Filed May 24, 2021 16:36 UTC |
Collar Mark ADirector
|
GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035335 · doc4.xml · nonDerivative · entry 1 Collar Mark A · CIK 0001426353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,307 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:40 UTC |
Florin Daniel PDirector
|
GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035340 · doc4.xml · nonDerivative · entry 1 Florin Daniel P · CIK 0001402459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,103 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:46 UTC |
JOHNSON B KRISTINEDirector
|
GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035353 · doc4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,871 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:55 UTC |
WEHRWEIN SVENDirector
|
GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035369 · doc4.xml · nonDerivative · entry 1 WEHRWEIN SVEN · CIK 0001205069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,435 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 20, 2021 Filed May 25, 2021 00:08 UTC |
WHITE ROBERT S.Director
|
GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035552 · doc4.xml · nonDerivative · entry 1 WHITE ROBERT S. · CIK 0001571208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,235 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:52 UTC |
Prange KarenDirector
|
GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035362 · doc4.xml · nonDerivative · entry 1 Prange Karen · CIK 0001566083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,103 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:43 UTC |
GROVES REGINA EDirector
|
GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035348 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,558 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 10, 2021 Filed May 11, 2021 12:46 UTC |
Drake Scott WilliamDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,631 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-21-031479 · doc4.xml · derivative · entry 6 Drake Scott William · CIK 0001527909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,728 Underlying: Common Stock · 4,631 shares Expires 2023-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on September 3, 2013. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| May 10, 2021 Filed May 11, 2021 12:46 UTC |
Drake Scott WilliamDirector
|
SaleCommon Stock | 4,631 | $76.52 | $354,364.12 |
DisclosureSEC source: 0001209191-21-031479 · doc4.xml · nonDerivative · entry 4 Drake Scott William · CIK 0001527909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,036 F2 · price: This transaction was executed in multiple trades at prices ranging from $76.00 to $76.84 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 11, 2021 12:46 UTC |
Drake Scott WilliamDirector
|
Exercise / conversionCommon Stock | 4,631 | $8.98 | $41,586.38 |
DisclosureSEC source: 0001209191-21-031479 · doc4.xml · nonDerivative · entry 3 Drake Scott William · CIK 0001527909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2021 Filed May 11, 2021 12:46 UTC |
Drake Scott WilliamDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 38,641 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-21-031479 · doc4.xml · derivative · entry 5 Drake Scott William · CIK 0001527909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,359 Underlying: Common Stock · 38,641 shares Expires 2023-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on September 3, 2013. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| May 07, 2021 Filed May 11, 2021 12:46 UTC |
Drake Scott WilliamDirector
|
SaleCommon Stock | 38,641 | $77.90 | $3,010,133.90 |
DisclosureSEC source: 0001209191-21-031479 · doc4.xml · nonDerivative · entry 2 Drake Scott William · CIK 0001527909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,036 F1 · price: This transaction was executed in multiple trades at prices ranging from $77.52 to $79.13 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 07, 2021 Filed May 11, 2021 12:46 UTC |
Drake Scott WilliamDirector
|
Exercise / conversionCommon Stock | 38,641 | $8.98 | $346,996.18 |
DisclosureSEC source: 0001209191-21-031479 · doc4.xml · nonDerivative · entry 1 Drake Scott William · CIK 0001527909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2021 Filed May 10, 2021 08:18 UTC |
Collar Mark ADirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001209191-21-031116 · doc4.xml · derivative · entry 3 Collar Mark A · CIK 0001426353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on May 18, 2011 and are exercisable cumulatively at a rate of 33% per annum beginning one year from date of grant. Read SEC document |
| May 06, 2021 Filed May 10, 2021 08:18 UTC |
Collar Mark ADirector
|
Exercise / conversionCommon Stock | 10,000 | $14.17 | $141,700.00 |
DisclosureSEC source: 0001209191-21-031116 · doc4.xml · nonDerivative · entry 1 Collar Mark A · CIK 0001426353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2021 Filed May 6, 2021 12:07 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
GiftCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030536 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,808 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| May 05, 2021 Filed May 7, 2021 08:07 UTC |
Lanning Mark RDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001209191-21-030782 · doc4.xml · derivative · entry 3 Lanning Mark R · CIK 0001353679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on May 18, 2011 and are exercisable cumulatively at a rate of 33% per annum beginning one year from date of grant. Read SEC document |
| May 05, 2021 Filed May 7, 2021 08:07 UTC |
Lanning Mark RDirector
|
Exercise / conversionCommon Stock | 10,000 | $14.17 | $141,700.00 |
DisclosureSEC source: 0001209191-21-030782 · doc4.xml · nonDerivative · entry 1 Lanning Mark R · CIK 0001353679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 11:58 UTC |
WEHRWEIN SVENDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.95 | $0.00 |
DisclosureSEC source: 0001209191-21-030182 · doc4.xml · derivative · entry 4 WEHRWEIN SVEN · CIK 0001205069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 5,000 shares Expires 2026-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on November 11, 2016. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| May 03, 2021 Filed May 5, 2021 11:58 UTC |
WEHRWEIN SVENDirector
|
SaleCommon Stock | 5,000 | $78.19 | $390,950.00 |
DisclosureSEC source: 0001209191-21-030182 · doc4.xml · nonDerivative · entry 3 WEHRWEIN SVEN · CIK 0001205069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,686 F2 · price: This transaction was executed in multiple trades at prices ranging from $78.07 to $78.57 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2021 Filed May 5, 2021 11:58 UTC |
WEHRWEIN SVENDirector
|
Exercise / conversionCommon Stock | 5,000 | $19.95 | $99,750.00 |
DisclosureSEC source: 0001209191-21-030182 · doc4.xml · nonDerivative · entry 2 WEHRWEIN SVEN · CIK 0001205069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 11:58 UTC |
WEHRWEIN SVENDirector
|
SaleCommon Stock | 5,000 | $77.75 | $388,750.00 |
DisclosureSEC source: 0001209191-21-030182 · doc4.xml · nonDerivative · entry 1 WEHRWEIN SVEN · CIK 0001205069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,686 F1 · price: This transaction was executed in multiple trades at prices ranging from $77.50 to $78.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2021 Filed Oct 29, 2021 20:30 UTC |
GROVES REGINA EDirector
|
PurchaseCommon Stock | 34 | $76.68 | $2,607.12 |
DisclosureSEC source: 0001209191-21-062074 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,228 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 08:07 UTC |
Collar Mark ADirector
|
SaleCommon Stock | 3,000 | $65.28 | $195,840.00 |
DisclosureSEC source: 0001209191-21-024940 · doc4.xml · nonDerivative · entry 1 Collar Mark A · CIK 0001426353 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,558 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.35 to $65.81 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:28 UTC |
Wirick Angela LChief Financial Officer
|
Tax withholdingCommon Stock | 6,335 | $66.31 | $420,073.85 |
DisclosureSEC source: 0001209191-21-017255 · doc4.xml · nonDerivative · entry 2 Wirick Angela L · CIK 0001819885 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,667 F2 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. F3 · balance_after: Includes 3,417 shares acquired under the AtriCure, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:28 UTC |
Wirick Angela LChief Financial Officer
|
GrantCommon Stock | 3,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017255 · doc4.xml · nonDerivative · entry 1 Wirick Angela L · CIK 0001819885 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,002 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:23 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
Tax withholdingCommon Stock | 13,840 | $66.31 | $917,730.40 |
DisclosureSEC source: 0001209191-21-017240 · doc4.xml · nonDerivative · entry 3 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,108 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:23 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
GrantCommon Stock | 6,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017240 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,948 F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:23 UTC |
Noznesky Justin JChief Mktg & Strategy Officer
|
GrantCommon Stock | 7,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017240 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,539 F1 · price: The Reporting person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Equity Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:17 UTC |
CARREL MICHAEL HDirector · President, CEO, & Director
|
Tax withholdingCommon Stock | 55,241 | $66.31 | $3,663,030.71 |
DisclosureSEC source: 0001209191-21-017211 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,290 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.